Theseus Pharmaceuticals (Theseus Pharmaceuticals) EV-to-EBIT

: 0.30 (As of Today)

View and export this data going back to 2021. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Theseus Pharmaceuticals's Enterprise Value is $-20.19 Mil. Theseus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-66.52 Mil. Therefore, Theseus Pharmaceuticals's EV-to-EBIT for today is 0.30.

The historical rank and industry rank for Theseus Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

THRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -76959.21 Med: 0 Max: 17668.68
Current: 0.3

During the past 4 years, the highest EV-to-EBIT of Theseus Pharmaceuticals was 17668.68. The lowest was -76959.21. And the median was 0.00.

THRX's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 8.325 vs THRX: 0.30

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Theseus Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2023 was $-84.17 Mil. Theseus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-66.52 Mil. Theseus Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 79.04%.

Theseus Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Theseus Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theseus Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

EV-to-EBIT

-9.00

0.02

Theseus Pharmaceuticals Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EV-to-EBIT	Get a 7-Day Free Trial										-0.34	0.02	-2.55	-3.06	1.27

Competitive Comparison

For the Biotechnology subindustry, Theseus Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theseus Pharmaceuticals EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Theseus Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Theseus Pharmaceuticals's EV-to-EBIT falls into.

Theseus Pharmaceuticals EV-to-EBIT Calculation

Theseus Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-20.190	/	-66.524
	=	0.30

Theseus Pharmaceuticals's current Enterprise Value is $-20.19 Mil.
Theseus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.52 Mil.

Theseus Pharmaceuticals (NAS:THRX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Theseus Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 )	=	EBIT	/	Enterprise Value (Q: Sep. 2023 )
	=	-66.524	/	-84.168281
	=	79.04 %

Theseus Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2023 was $-84.17 Mil.
Theseus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.52 Mil.

Theseus Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Theseus Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Theseus Pharmaceuticals (Theseus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theseus Pharmaceuticals Inc (NAS:THRX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 Main Street, Cambridge, MA, USA, 02142

Website

https://www.theseusrx.com

Theseus Pharmaceuticals Inc is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer.

Executives

Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Foresite Capital Fund V, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Hayden Donald J Jr	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bradford D. Dahms	officer: Chief Financial Officer	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Timothy P Clackson	director, officer: President and CEO	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Steven H Stein	director	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Foresite Capital Opportunity Management V, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Opportunity Fund V, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Management V, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
James B. Tananbaum	10 percent owner	3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
William Shakespeare	officer: See Remarks	245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Rock Springs Capital Master Fund Lp	10 percent owner	190 ELGIN AVENUE, GEORGE TOWN E9 KY1 9001
Omega Fund Vi Gp Manager, Ltd.	10 percent owner	888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Orbimed Capital Gp Vii Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022